Ensoma

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach using Engenious vectors. These vectors are engineered to facilitate the delivery of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the need for stem cell collection or harmful pre-treatment procedures like chemotherapy. This unique capability allows Ensoma to administer therapies through a single injection, making it possible to deliver effective treatments in outpatient settings and areas with limited access to advanced healthcare systems. By streamlining the process of gene therapy, Ensoma aims to enhance the accessibility and curative potential of genomic medicine for patients with various diseases.

Paula Soteropoulos

Chairman of the Board

1 past transactions

Twelve bio

Acquisition in 2023
Twelve Bio specializes in CRISPR-Cas12a diagnostic technology, which enables the detection and modification of specific DNA sequences. This technology functions through an RNA-protein complex, where the RNA acts as a search engine to locate targeted DNA sequences, while the protein serves as a precision cutter. The company's diagnostic test is particularly focused on early-stage lung cancer detection through a blood test. Additionally, Twelve Bio offers a gene-editing toolbox aimed at addressing various genetic disorders, providing tailored solutions that enhance treatment accessibility and affordability for patients facing severe health challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.